One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

Ségolène Hescot; Sophie Leboulleux; Laurence Amar; Delphine Vezzosi; Isabelle Borget; Claire Bournaud-Salinas; Christelle de la Fouchardiere; Rossella Libé; Christine Do Cao; Patricia Niccoli; Antoine Tabarin; Isabelle Raingeard; Cécile Chougnet; Sophie Giraud; Anne-Paule Gimenez-Roqueplo; Jacques Young; Francoise Borson-Chazot; Jér?me Bertherat; Jean-Louis Wemeau; Xavier Bertagna; Pierre-Francois Plouin; Martin Schlumberger; Eric Baudin

首页> 外文期刊>The journal of clinical endocrinology and metabolism >One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

【24h】

One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

机译：单纯性恶性嗜铬细胞瘤和副神经节瘤患者的一年无进展生存期

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Context:The natural history of malignant pheochromocytoma or paragangliomas (MPP) remain unknown.

机译：背景：恶性嗜铬细胞瘤或神经节瘤（MPP）的自然史仍未知。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2013年第10期|共7页
作者
Ségolène Hescot; Sophie Leboulleux; Laurence Amar; Delphine Vezzosi; Isabelle Borget; Claire Bournaud-Salinas; Christelle de la Fouchardiere; Rossella Libé; Christine Do Cao; Patricia Niccoli; Antoine Tabarin; Isabelle Raingeard; Cécile Chougnet; Sophie Giraud; Anne-Paule Gimenez-Roqueplo; Jacques Young; Francoise Borson-Chazot; Jér?me Bertherat; Jean-Louis Wemeau; Xavier Bertagna; Pierre-Francois Plouin; Martin Schlumberger; Eric Baudin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas [J] . Asai Shiko, Katabami Takuyuki, Tsuiki Mika, Hormones & cancer . 2017,第2期

机译：用环磷酰胺，长春螯唑治疗控制肿瘤进展，改善了转移和不可切除的恶性嗜肺癌患者的存活率
2. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas [J] . Pierre Charlie, Agopiantz Mikael, Brunaud Laurent, Virchows Archiv: an international journal of pathology . 2019,第6期

机译：COPP，综合评分集成了病理特征，PS100和SDHB损失，预测了嗜铬细胞瘤/巴拉邦族瘤中转移和无进展生存的风险
3. Malignant pheochromocytoma and paraganglioma: A population level analysis of long-term survival over two decades [J] . GoffredoP., SosaJ.A., RomanS.A. Journal of Surgical Oncology . 2013,第6期

机译：恶性嗜铬细胞瘤和副神经节瘤：二十年来长期生存的人群水平分析
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Association of patient-reported outcomes with progression-free survival in malignant pleural mesothelioma. [D] . Hackshaw, Michelle Denise. 2010

机译：患者报告的结局与恶性胸膜间皮瘤无进展生存的相关性。
6. Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer [O] . Camilo Jimenez 2018

机译：恶性嗜铬细胞瘤和神经节旁瘤的治疗：癌症的标志
7. One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma [O] . Ségolène Hescot, Sophie Leboulleux, Laurence Amar, 2013

机译：治疗的治疗危险患者和恶性嗜尼胞细胞瘤和伞菌患者的一年的无进展存活

One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma

摘要

著录项

相似文献

相关主题

期刊订阅